News Hims & Hers to offer unapproved peptides to customers Telehealth firm Hims & Hers will soon start selling some unapproved peptides subject to the FDA's enforcement discretion policy announced last month.
News FDA orders blindness risk warning to GLP-1 agonist labels FDA has ordered all GLP-1 receptor agonist manufacturers to add a warning to their product labels for a rare eye condition that can cause blindness.
News Bayer bags FDA green light for stroke drug Sunharbo Bayer gets FDA nod for first-in-class oral Factor XIa inhibitor Sunharbo, a potential blockbuster, for secondary stroke prevention.
News Amazon puts $100m into global health drive Amazon Web Services has committed $100m in AI and cloud technology capacity to support the building of health services for "underserved communities."
News MHRA grants Innovation Passports to three novel drugs The MHRA has awarded Innovation Passports to three drugs that could offer a step forwards in treating lung cancer, Huntington's, and Alzheimer's.
News argenx agrees Unnatural takeover deal worth up to $1.15bn argenx has agreed its second acquisition of the year, buying macrocyclic peptide drug developer Unnatural Products for $550m upfront.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.